Méningiomes de la base du crâne : efficacité et tolérance clinique, efficacité radiologique et cinétique tumorale après radiothérapie

Brahimi, Youssef; Antoni, D.; Srour, Robin; Proust, F.; Cébula, H.; Labani, Aïssam; Noël, G.

doi:10.1016/j.canrad.2017.09.010

Cited by 4 publications

(2 citation statements)

References 122 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In such cases, irradiation can be proposed, however few datas focused on the potential onset of radiotherapy-induced pituitary deficiencies. If untreated, the latter have a negative impact on quality of life [ 6 , 7 ]. Hypopituitarism has been shown to increase morbi-mortality, and more specifically in young women with untreated gonadotroph deficiency [ 8 , 9 ], and at-risk patients therefore require a regular follow-up to both diagnose and treat the outcome of hormonal deficiency (ies).…”

Section: Introductionmentioning

confidence: 99%

High prevalence of anterior pituitary deficiencies after cranial radiation therapy for skull base meningiomas

et al. 2021

View full text Add to dashboard Cite

Background Cranial irradiation represents one of the first line treatment proposed in skull base meningiomas. While cranial irradiation is associated with a high risk of secondary hypopituitarism, few studies focused on the specific location of skull base meningiomas. Methods Fifty-two adults receiving photon-beam therapy for skull base meningiomas between 2003 and 2014 in our Institution were included. Anterior pituitary (ACTH, FSH, GH, LH, TSH and prolactin) as well as corresponding peripheral hormones (8 am-Cortisol, IGF-1, fT3, fT4, 17βestradiol or testosterone) were biologically screened before radiotherapy (baseline), then yearly until March 2019. The pituitary gland (PG) was delineated on CT and the mean dose delivered to it was calculated. Results Mean age at diagnosis was 56 +/− 14 years. Median follow-up was 7 years. Up to 60% of patients developed at least ≥2 pituitary deficiencies, 10 years after radiotherapy. Gonadotroph, thyrotroph, corticotroph and somatotroph deficiencies occurred in 37, 28, 18 and 15% of patients, respectively. Hyperprolactinemia was found in 13% of patients. None patient had only one pituitary deficiency. In the multivariate analysis, a delivered dose to the PG ≥ 50 Gy or a meningioma size ≥40 mm significantly increased the risk of developing hypopituitarism. Conclusions Over a long-term follow-up, cranial radiation therapy used in skull base meningiomas led to a high prevalence of hypopituitarism, further pronounced in case of tumor ≥4 cm. These results advocate for an annual and prolonged follow-up of the pituitary functions in patients with irradiated skull base meningiomas.

show abstract

Section: Introductionmentioning

confidence: 99%

High prevalence of anterior pituitary deficiencies after cranial radiation therapy for skull base meningiomas

et al. 2021

View full text Add to dashboard Cite

show abstract

“…In such cases, cranial irradiation is one of the best treatment options, however few datas focused on the potential onset of radiotherapy-induced pituitary deficiencies. If untreated, the latter have a negative impact on quality of life (5,6).…”

Section: Introductionmentioning

confidence: 99%

High Prevalence of Anterior Pituitary Deficiencies after Cranial Radiation Therapy for Skull Base Meningiomas. 

Raymond

Klein

Cuny

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: Cranial irradiation represents the first-line treatment proposed in skull base meningiomas. While cranial irradiation is associated with a high risk of secondary hypopituitarism, few studies focused on the specific location of skull base meningiomas. Methods: 52 adults receiving photon-beam therapy for skull base meningiomas between 1978 and 2014 in our Institution were included. Anterior pituitary (ACTH, FSH, GH, LH, TSH and prolactin) as well as corresponding peripheral hormones (8am-Cortisol, IGF-1, fT3, fT4, 17βestradiol or testosterone) were biologically screened before radiotherapy (baseline), then yearly until March 2019. The pituitary gland (PG) was delineated on CT and the mean dose delivered to it was calculated.Results: Mean age at diagnosis was 56 +/-14 years. Median follow-up was 7 years. Up to 60% of patients developed at least ≥ 2 pituitary deficiencies, 10 years after radiotherapy. Gonadotroph, thyrotroph, corticotroph and somatotroph deficiencies occurred in 37%, 28%, 18% and 15% of patients, respectively. Hyperprolactinemia was found in 13 % of patients. None patient had only one pituitary deficiency. In the multivariate analysis, a delivered dose to the PG ≥ 50 Gy or a meningioma size ≥ 40 mm significantly increased the risk of developing hypopituitarism. Conclusions: Over a long-term follow-up, cranial radiation therapy used in skull base meningiomas led to a high prevalence of hypopituitarism, further pronounced in case of tumor ≥ 4cm. These results advocate for an annual and prolonged follow-up of the pituitary functions in patients with irradiated skull base meningiomas.

show abstract

Ionentherapie – ein Überblick

Mattke

Debus

2019

Onkologe

View full text Add to dashboard Cite

Méningiomes de la base du crâne : efficacité et tolérance clinique, efficacité radiologique et cinétique tumorale après radiothérapie

Cited by 4 publications

References 122 publications

High prevalence of anterior pituitary deficiencies after cranial radiation therapy for skull base meningiomas

High prevalence of anterior pituitary deficiencies after cranial radiation therapy for skull base meningiomas

High Prevalence of Anterior Pituitary Deficiencies after Cranial Radiation Therapy for Skull Base Meningiomas.

Ionentherapie – ein Überblick

Contact Info

Product

Resources

About

Méningiomes de la base du crâne : efficacité et tolérance clinique, efficacité radiologique et cinétique tumorale après radiothérapie

Cited by 4 publications

References 122 publications

High prevalence of anterior pituitary deficiencies after cranial radiation therapy for skull base meningiomas

High prevalence of anterior pituitary deficiencies after cranial radiation therapy for skull base meningiomas

High Prevalence of Anterior Pituitary Deficiencies after Cranial Radiation Therapy for Skull Base Meningiomas.&nbsp;

Ionentherapie – ein Überblick

Contact Info

Product

Resources

About

High Prevalence of Anterior Pituitary Deficiencies after Cranial Radiation Therapy for Skull Base Meningiomas.